🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesArterial stiffness reduction on GLP-1 — pulse wave velocity studies

Arterial stiffness reduction on GLP-1 — pulse wave velocity studies

Dr.RaviCardio Thu, May 21, 2026 at 5:24 AM 13 replies 517 viewsPage 1 of 3
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
May 21, 2026 at 5:24 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. The effect appeared earlier than the weight-loss curve can comfortably explain, which is the basis for arguing that some of the benefit is direct — anti-inflammatory and vascular — rather than purely a consequence of weight.

Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.

So the question, as narrowly as I can put it: how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
49 19pete_manc_UK, anna.melb_AU, mark_tokyo and 46 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
May 21, 2026 at 6:36 AM#2
Dr.RaviCardio said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 71 pg/mL (normal, cardiac function preserved)
  • Lp(a): 61 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 151 to 96 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

48 18PharmHunterJen, TomTeleRx, DoseLogDan and 45 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
May 21, 2026 at 7:48 AM#3
Dr.RaviCardio said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

This is where I part company with the consensus forming above. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

47 17lori_vegas, Dr.PulmRoch, maya_sedona and 44 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
May 21, 2026 at 9:00 AM#4
BethLabQueen said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

11 months later: down 58 lbs, off atorvastatin, A1C from 7.6% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: May 21, 2026 at 11:00 AM
46 16Dr.ObesityMed, HealthEcon_DC, PedsEndoPhilly and 43 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
May 21, 2026 at 3:55 PM#5
TrialNerd_Beth said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Can confirm. Same sequence, different timescale. Posting only so the count is not one.

45 15BethLabQueen, ChrisMacros, KetoKyle and 42 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register